Al Mayadeen English

  • Ar
  • Es
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Al Mayadeen's correspondent: A batch of incendiary balloons were launched towards settlements adjacent to the Gaza Strip.
Turkey's Defense Ministry: 5 Kurdistan Workers Party members killed in an airstrike in northern Iraq.
The Iranian Intelligence Ministry says its forces raided several terrorist hideouts in Tehran and Western Azerbaijan and arrested 28 elements.
Iran's Intelligence Ministry says the terror attacks were aimed at undermining Iran's state security and showing Iran as a destabilized nation.
Iran's Intelligence Ministry says it foiled a terrorist plot being planned for Tehran, with all the culprits getting arrested.
Iranian Defense Ministry says has missiles designed with the intention of striking the Israeli occupation, namely the Hajj Qassem Soleimani missile.
Al Mayadeen correspondent: The Israeli occupation forces raided Birzeit University and arrested three young men in its vicinity.
Al Mayadeen correspondent: The Israeli occupation forces raided the Nur Shams refugee camp in Tulkarm for several hours, with snipers deployed on the rooftops.
China inaugurates the Asian games in Hangzhou.
The Israeli soldiers launched smoke and sound grenades at the Lebanese side earlier.

New drug could stop breast cancer variant from returning by 25%

  • By Al Mayadeen English
  • Source: News Websites
  • 2 Jun 2023 18:15

Thousands of women with the world's most prevalent form of breast cancer might benefit from a medicine that reduces their chances of relapse by a quarter.

  •  A radiologist uses a magnifying glass to check mammograms for breast cancer in Los Angeles, May 6, 2010 (AP Photo/Damian Dovarganes, File)
    A radiologist uses a magnifying glass to check mammograms for breast cancer in Los Angeles, May 6, 2010 (AP Photo/Damian Dovarganes, File)

Thousands more women with the world's most prevalent form of breast cancer might benefit from an innovative medicine that extends their lives and reduces their chances of relapse by a quarter.

Every year, more than 2 million women are diagnosed with the illness, which is the most common cancer in the world. Despite advances in treatment in recent decades, many individuals may experience cancer recurrence. If a recurrence occurs, it is usually at a later stage.

A promising study was revealed at the world's biggest cancer conference, the American Society of Clinical Oncology (Asco), indicating that ribociclib, a novel targeted treatment medicine, might be a game changer. According to trial data, it can improve survival and dramatically reduce the likelihood of cancer recurrence.

Ribociclib has previously been proven to improve survival in people with advanced breast cancer. However, researchers observed in a recent study that it may also improve outcomes for people with much earlier-stage illnesses, such as in the case where cancer has not yet reached lymph nodes.

The findings piqued the interest of researchers and oncologists at Asco's annual meeting in Chicago since the evidence shows that the medicine, also known as Kisqali, might prevent cancer from returning in a large population and influence global practice.

Ribociclib is a small molecule inhibitor, which is a type of targeted treatment. It acts by targeting CDK4 and CDK6 proteins in breast cancer cells, which regulate cell proliferation, including cancer cell growth.

The medicine reduced the chance of recurrence by 25% when administered in conjunction with normal hormone therapy compared to hormone therapy alone following traditional therapies, according to a late-stage experiment, and has been licensed by authorities in the UK and the US. 

Because of the large number of people it potentially aids, the earlier-stage setting, when tumors can still be surgically removed, is considered a far greater breakthrough.

Patients with breast cancer are often offered surgery, chemotherapy, or radiation treatment before being prescribed hormone-blocking medicines to try to prevent the illness from reoccurring.

Related News

184,000 in UK to get preventable cancer diagnosis this year: Study

NHS doubles wait time for cancer patients

The study discovered that combining ribociclib with hormone treatment resulted in a "significant improvement" in disease-free survival durations for patients with hormone receptor-positive, HER2-negative early-stage breast cancer.

Hormone receptor-positive, HER2-negative breast cancer is the most common subtype of the disease, making up nearly 70% of all breast cancer cases in the US.

According to lead author Dr. Dennis Slamon, “Currently, approved targeted treatments can only be used in a small population of patients diagnosed with hormone receptor-positive, HER2-negative early breast cancer, leaving many without an effective treatment option for reducing risk of the cancer returning."

Slamon explained that nearly one-third of people with stage two hormone receptor-positive HER2-negative will have a relapse after treatment and more than half with stage 3 will have the cancer make a full return.

“Thus, there is a significant unmet need for both reducing the risk of recurrence and providing a tolerable treatment option that keeps patients cancer-free without disrupting their daily life.”

The Natalee study involved 5,101 patients who were given either ribociclib for three years alongside five years of hormonal therapy or the hormonal therapy alone.

After three years, 90.4% of those taking ribociclib remained free of disease, compared with 87.1% in the hormonal therapy alone group. Ribociclib also showed more favorable outcomes in overall survival, recurrence-free survival, and distant disease-free survival, according to the researchers.

Dr. Rita Nanda, an Asco expert in Chicago, stated that the results suggest " there will be a role for adjuvant ribociclib for stage two and higher hormone receptor-positive, HER2-negative breast cancer,”

Dr Catherine Elliott, director of research and partnerships at Cancer Research UK called the findings "promising" although more research is needed.

“The combination of ribociclib and hormonal therapy could provide a new treatment option for people with this type of early-stage breast cancer, reducing the risk of the disease coming back and improving survival.”

  • Breast cancer
  • Cancer

Most Read

Ukrainian soldiers ride an APC on the front line near Bakhmut, in the Donetsk region, on June 5, 2023 (AP)

US sees Ukrainian army demoralized, no chance to win: Seymour Hersh

  • Europe
  • 21 Sep 2023
Russia destroyed leopard tank in Ukraine with fully-German crew

Russia destroyed leopard tank in Ukraine with fully-German crew

  • Europe
  • 23 Sep 2023
British mercenary in Ukraine killed by another Brit

British mercenary in Ukraine killed by another Brit

  • Europe
  • 18 Sep 2023
Army Chief of Staff Gen. Mark A. Milley testifies on Capitol Hill in Washington, Wednesday, April 5, 2017, before the House Armed Services Committee hearing: 'Damage to the Military from a Continuing Resolution. (AP)

US should avoid open armed conflict with China: Top US general

  • Politics
  • 17 Sep 2023

Coverage

All
Morocco & Libya Disasters

Read Next

All
Saudi Arabian Foreign Minister Prince Faisal bin Farhan Al Furhan Al-Saud addresses the 78th session of the United Nations General Assembly, Saturday, Sept. 23, 2023, at United Nations headquarters. (AP)
Palestine

Saudi FM tells UN regional stability hinges on 'Palestinian state'

Nearly two weeks later, Libya toll tops 3,800
MENA

Nearly two weeks later, Libya toll tops 3,800

A man walks past a mural featuring oil pumps and wells in Caracas, Venezuela, Saturday, May 21, 2022. (AP)
Latin America

Venezuela boosts oil production amid unilateral restrictive measures

Russia destroyed leopard tank in Ukraine with fully-German crew
Europe

Russia destroyed leopard tank in Ukraine with fully-German crew

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS